A Phase II, Multicentre, Randomised, Placebo-controlled, Doublemasked Trial of RP101 Ophthalmic Formulation Versus Vehicle in Post-menopausal Women With Moderate to Severe Dry Eye Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs RP 101-Redwood Pharma (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Redwood Pharma
- 12 Nov 2019 According to a Redwood Pharma media release, last patient received their last dose, Thus, the treatment phase in the clinical trial is finished. Company is now working on collecting and quality-assuring the extensive material in order to then analyze the results.
- 05 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2019 According to a Redwood Pharma media release, approximately 100 patients are evaluated during a treatment period of three months, after which the study ends with a follow-up after the last dose has been administered. Topline results are expected to be published no later than the first quarter of 2020.